Mr. Hoffman has over 18 years of capital markets & investment banking experience and has completed over 100 private & public equity transactions, representing over $4 billion in aggregate value. He is focused on the life sciences sector and has raised capital for a diverse set of biotechnology, specialty pharmaceutical, medical device and healthcare technology companies across a wide range of structures including IPOs, Secondaries/ Follow-on Offerings, SPACs, Registered Directs, PIPEs, Privates, Fairness Opinions and M&A mandates. Prior to joining Maxim, Mr. Hoffman was concurrently a Managing Director at Torreya Partners and the Head of Business Development at Claravant Analytics, a clinical & regulatory consulting firm. Mr. Hoffman’s diverse professional experience also includes over a decade of healthcare institutional sales at Lazard Capital Markets and at Oppenheimer & Co Inc., as well as, over 3 years of investor relations consulting at the Carson Group. He holds a BA from Wesleyan University, speaks French fluently, is a CFA Charterholder and currently holds FINRA series 7, 63 and 79 licenses.
Bradford M. Hoffman, CFA